Request Trial
izzuanroslan / Shutterstock.com
27 July 2026NewsRegulation & IndustryMarisa Woutersen

Buying the brains: Why is Big Pharma shopping for innovation?

With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
Trump slaps 100% tariff on generic drugs in US manufacturing push
23 July 2026   Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.
Regulation & Industry
UK Prime Minister axes science ministry in govt shakeup
22 July 2026   Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation.
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026   Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.


Editor's picks

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

Editor's picks

Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Regulation & Industry
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Regulation & Industry
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

FisherBroyles and Hong Kong affiliate draft in senior partners
‘Engagement and collaboration’: New IP Federation president builds on strong foundations
AbbVie, Allergan takes on Swiss aesthetics rival over syringe design
Trump slaps 100% tariff on generic drugs in US manufacturing push
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
UK Prime Minister axes science ministry in govt shakeup
Masimo keeps $634m smartwatch award and moves to appeal
Arbutus takes Comirnaty LNP patent fight to Canada and UPC